Top Page
OncoSil Medical Ltd
(Sydney:OSL)
OncoSil Medical Ltd (OSL) vs. iShares MSCI Australia ETF (EWA)
OncoSil Medical Ltd Business Overview & Revenue Model
OncoSil Medical Ltd Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 516.63K | 367.68K | 231.79K | 213.07K | 2.76M |
| Gross Profit | -993.00K | -1.22M | -741.00K | -748.00K | 2.62M |
| EBITDA | -11.87M | -11.17M | -11.41M | -10.25M | -4.11M |
| Net Income | -11.91M | -11.34M | -10.73M | -10.43M | -4.26M |
Balance Sheet | |||||
| Total Assets | 6.72M | 11.47M | 13.07M | 14.15M | 24.06M |
| Cash, Cash Equivalents and Short-Term Investments | 4.50M | 9.39M | 11.28M | 12.24M | 21.00M |
| Total Debt | 70.67K | 170.81K | 304.21K | 484.37K | 109.94K |
| Total Liabilities | 1.98M | 1.59M | 1.91M | 2.45M | 2.16M |
| Stockholders Equity | 4.74M | 9.88M | 11.16M | 11.70M | 21.90M |
Cash Flow | |||||
| Free Cash Flow | -11.02M | -11.37M | -10.12M | -8.87M | -4.48M |
| Operating Cash Flow | -10.82M | -11.32M | -10.11M | -8.82M | -4.46M |
| Investing Cash Flow | -197.06K | -57.82K | -5.83K | -54.00K | -20.72K |
| Financing Cash Flow | 6.13M | 9.49M | 9.16M | 111.25K | 17.79M |
OncoSil Medical Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$155.96M | ― | -52.37% | ― | 471.29% | -4.58% | |
51 Neutral | $7.39B | 0.36 | -62.86% | 2.37% | 15.48% | -2.68% | |
49 Neutral | AU$50.04M | ― | -135.33% | ― | -27.58% | 33.69% | |
46 Neutral | AU$147.09M | ― | -58.61% | ― | ― | -74.88% | |
44 Neutral | AU$13.26M | ― | -98.08% | ― | -7.44% | 30.34% | |
43 Neutral | AU$20.52M | ― | -199.38% | ― | 271.05% | 42.55% | |
41 Neutral | AU$109.47M | ― | -35.20% | ― | 4.68% | -155.42% |
OncoSil Medical Ltd Corporate Events
OncoSil Medical Ltd reported a strong quarter with record dose sales in Q4 FY25, driven by increased clinical adoption and demand from treatment centers. The company achieved a 20% increase in dose sales compared to the previous quarter and a 42% increase for the full fiscal year, leading to a 66% rise in annual revenue. Additionally, OncoSil Medical completed a successful $8.7 million capital raise to support commercialization efforts and signed a distribution agreement for Slovenia. The company also announced a significant clinical study in Germany, which could enhance its market positioning by generating evidence for national reimbursement. Furthermore, a comparative study presented at Digestive Disease Week 2025 demonstrated superior outcomes for patients treated with OncoSil™ compared to Stereotactic Body Radiation Therapy, highlighting its potential as a valuable treatment option.
OncoSil Medical Limited has announced the resignation of Mr. Nathan Kim-liung Jong as Company Secretary and the appointment of Ms. Olga Smejkalova to the role, effective immediately. Ms. Smejkalova brings extensive experience in corporate governance and compliance, which is expected to enhance the company’s operations. This change in leadership is poised to strengthen OncoSil’s industry positioning as it continues to commercialize its innovative cancer treatment technology.
OncoSil Medical Ltd has successfully completed patient recruitment for its TRIPP-FFX clinical trial, a significant milestone in its clinical development strategy. The trial evaluates the safety and efficacy of the OncoSil™ device combined with FOLFIRINOX chemotherapy in patients with locally advanced pancreatic cancer. This achievement accelerates the device’s clinical development and supports its broader adoption. Data from the study is expected in early 2026, potentially impacting the company’s market positioning and offering new therapeutic options for pancreatic cancer treatment.
Soul Patts has announced a change in its substantial holding in OncoSil Medical Ltd, as required under the Corporations Act 2001. The change reflects Soul Patts’ increased voting power in Pengana Capital Group Limited, now holding more than 20% of the ordinary shares, which impacts its interests in OncoSil Medical Ltd. This development may influence Soul Patts’ strategic positioning and stakeholder interests in the investment landscape.
OncoSil Medical Ltd has announced a change in the interests of a substantial holder as of July 11, 2025. This change in voting power and relevant interests could impact the company’s governance and decision-making processes, potentially influencing its strategic direction and stakeholder relationships.
OncoSil Medical Ltd, a company involved in the medical industry, has experienced a change in the interests of a substantial shareholder. Australian Ethical Investment Limited has increased its voting power in OncoSil Medical Ltd from 5.15% to 6.93%, indicating a growing interest and potential influence in the company’s decision-making processes.
OncoSil Medical Ltd has announced the application for quotation of new securities on the Australian Securities Exchange (ASX), including 7,740 ordinary fully paid shares and 7,740 options expiring in July 2027. This move is part of the company’s strategic efforts to enhance its financial position and support its ongoing operations in the medical device sector, potentially impacting its market presence and offering new opportunities for stakeholders.
OncoSil Medical Ltd has announced the appointment of Thomas Duthy as a director, effective July 11, 2025. This strategic appointment is expected to enhance the company’s leadership team and potentially influence its future direction in the medical device sector, although specific implications for stakeholders were not detailed in the announcement.
OncoSil Medical Ltd has announced an analysis of its holdings, detailing the distribution of its listed options expiring on 31 July 2027. The analysis reveals that the majority of the company’s options are held by a small number of entities, with the top ten holders accounting for over 74% of the total units. This concentration of holdings may have implications for the company’s market dynamics and stakeholder influence.
OncoSil Medical Ltd has announced a new application for the quotation of securities on the ASX, involving the issuance of over 2.8 million ordinary fully paid shares and several classes of options set to expire in July 2027. This move is part of the company’s strategic efforts to enhance its financial position and support ongoing operations, potentially impacting its market presence and stakeholder interests.
OncoSil Medical Ltd has announced the application for quotation of new securities on the ASX. The company is set to quote 1,719,306 ordinary fully paid securities and an equal number of options expiring on July 31, 2027. This move is part of their strategic efforts to enhance their market presence and potentially increase funding for ongoing and future projects.
OncoSil Medical Ltd has announced the appointment of Dr. Thomas Duthy as a Non-Executive Director, effective July 11, 2025. Dr. Duthy brings over 21 years of experience in financial markets, corporate development, and board-level roles in the healthcare and life sciences sectors. His appointment comes as the company is experiencing strong clinical momentum with its PANCOSIL and TRIPP-FFX trials and expanding its treatment footprint across Europe. Dr. Duthy’s expertise in capital markets and strategic transactions is expected to be invaluable as OncoSil continues to scale its global presence and drive shareholder value.
OncoSil Medical Ltd has announced a proposed issue of securities, including options expiring in 2027 and ordinary fully paid shares, with a total of 17,271 securities to be issued. This move is part of a placement or other type of issue, and the company has applied for the quotation of these securities on the ASX. The issuance is set to take place on August 8, 2025, and is expected to support the company’s operations and strategic initiatives in the oncology market.
OncoSil Medical Ltd announced an update regarding the proposed issue of securities, following shareholder approval at the Extraordinary General Meeting (EGM) held on July 8, 2025. The update includes a consolidation of shares at a ratio of 1 for 400, as approved in a previous EGM on May 29, 2025. This move is part of the company’s strategy to streamline its capital structure and potentially enhance its market positioning, which could have significant implications for its stakeholders.
OncoSil Medical Ltd announced an update regarding the issuance of securities under a Securities Purchase Plan (SPP), which was approved by shareholders during an Extraordinary General Meeting (EGM) held on July 8, 2025. This update includes an amendment to the number of shares and options, reflecting a 1 for 400 consolidation approved earlier on May 29, 2025, and the final SPP issue price announced on July 7, 2025. This move is part of the company’s strategic financial adjustments, potentially impacting its market positioning and shareholder value.
OncoSil Medical Ltd announced that all resolutions proposed at their Extraordinary General Meeting were passed by poll. This outcome supports the company’s strategic initiatives, including the issuance of new shares and options, which could potentially strengthen its financial position and enhance its market operations.
OncoSil Medical Ltd has successfully completed a $2 million Share Purchase Plan (SPP), which was strongly supported and oversubscribed by shareholders, receiving applications for approximately $4.5 million. The funds raised will be used to invest in the company’s Macquarie Park manufacturing facility, fund clinical trials, and cover other working capital costs. This financial boost is expected to enhance OncoSil’s focus on commercial activities and clinical trials for label expansion, ultimately aiming for increased market access and operational leverage.
OncoSil Medical Ltd has announced that Australian Ethical Investment Limited has become a substantial holder in the company, with a 5.15% voting power through State Street Australia Ltd. This development indicates a significant investment interest in OncoSil Medical, potentially impacting its market perception and stakeholder confidence.
OncoSil Medical Ltd has announced a change in the director’s interest, with Lelde Smits acquiring 7,500 options under the company’s Long-Term Incentive (LTI) Scheme. This acquisition reflects the company’s ongoing efforts to align its leadership’s interests with long-term strategic goals, potentially impacting the company’s governance and stakeholder confidence.
OncoSil Medical Ltd announced the cessation of 3,494 ordinary fully paid securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could have implications for its market positioning and stakeholder interests.
OncoSil Medical Ltd has announced the issuance of 7,500 new unquoted equity securities, specifically options expiring on January 14, 2030, with an exercise price of $12.00. This move is part of the company’s strategic financial maneuvers, potentially impacting its market positioning and offering new opportunities for stakeholders.
Soul Patts has announced a change in its substantial holding in OncoSil Medical Ltd (OSL), as it now holds a voting power of more than 20% in Pengana Capital Group Limited (PCG). This change signifies an increased influence in PCG, which may impact the company’s strategic decisions and potentially affect stakeholders involved with both PCG and OSL.
OncoSil Medical Ltd has announced an Extraordinary General Meeting (EGM) scheduled for July 8, 2025, in Melbourne. This meeting is crucial for shareholders as it impacts their holdings, and they are encouraged to vote either in person or by proxy. The meeting will address significant business matters, and shareholders are advised to seek professional guidance if unsure about their voting decisions. This EGM could have implications for the company’s strategic direction and stakeholder interests.
OncoSil Medical Limited has completed a capital consolidation on a 1 for 400 basis, as approved by shareholders, to streamline its capital structure. This move is part of the company’s strategy to enhance its market position as it continues to commercialize its innovative cancer treatment technology. The consolidation is expected to impact trading, with normal trading on a post-consolidation basis set to commence on June 13, 2025.
OncoSil Medical Ltd has announced the opening of a Security Purchase Plan (SPP) for eligible shareholders, primarily in Australia and New Zealand. This plan allows shareholders to purchase up to $100,000 of new fully paid OncoSil ordinary shares without incurring brokerage or transaction costs. The offer includes one free attaching option for every new share issued, with the options having an exercise price of $0.003 each and an expiry date of July 31, 2027. The SPP aims to strengthen OncoSil’s financial position as it continues to commercialize its innovative cancer treatment technology.
OncoSil Medical Ltd has announced the issuance of over 1 billion ordinary shares without disclosure under the Corporations Act, in compliance with relevant legal provisions. This move reflects the company’s strategic financial maneuvers to potentially enhance its capital structure, which could influence its market position and stakeholder interests.
OncoSil Medical Ltd has announced a consolidation of its securities, which was approved by shareholders at an Extraordinary General Meeting on May 29, 2025. This reorganization affects various securities, including ordinary shares and options with different expiration dates, and is part of the company’s strategic efforts to streamline its capital structure and potentially enhance shareholder value.
OncoSil Medical Ltd announced that all resolutions at their Extraordinary General Meeting were carried by poll. This includes the approval of share consolidation, future issue of shares, an omnibus plan, and the issuance and ratification of options. The successful passing of these resolutions is expected to impact the company’s operational strategies and potentially enhance its market position, benefiting stakeholders by aligning with its growth objectives.
OncoSil Medical Ltd has announced a proposed issue of securities under a securities purchase plan, aiming to issue a total of 666,666,667 new securities. This move is likely to impact the company’s financial structure and could influence its market positioning by potentially increasing its capital base, which may be used for further development and expansion activities.
OncoSil Medical Ltd has announced a proposed issuance of securities, including options and ordinary shares, set to take place on July 11, 2025. This move is part of a strategic effort to raise capital, potentially enhancing the company’s financial position and supporting its ongoing operations and growth initiatives within the oncology sector.
OncoSil Medical Ltd has released a presentation regarding a capital raise, emphasizing that the information provided is not an offer for securities but rather a general overview of the company’s operations and future prospects. The presentation includes forward-looking statements about the company’s product candidates and their potential regulatory approvals, highlighting the risks and uncertainties involved. Stakeholders are advised to seek independent advice due to the speculative nature of the information presented.
OncoSil Medical Ltd has announced a Share Purchase Plan and Placement to raise approximately $8.7 million before offer costs, subject to shareholder approval. The capital raising initiative includes offering new shares and options to eligible shareholders and invited investors, with Bell Potter appointed as the Lead Manager. This move is expected to bolster the company’s financial position and support its ongoing operations and strategic initiatives in the medical device industry.
OncoSil Medical Ltd has announced an $8.7 million capital raise to accelerate the commercialization of its pancreatic cancer treatment device. The funds will support ongoing clinical trials and commercialization efforts, with a focus on expanding market access in Europe and existing jurisdictions. The capital raise includes a placement and a Share Purchase Plan (SPP), with strong backing from institutional investors, including Pengana High Conviction Equities Fund. The completion of two major clinical trials, PANCOsil and TRIPP-FFX, is expected to significantly enhance the company’s market access and operational cash flow by the second half of 2026.
OncoSil Medical Ltd has requested a trading halt on its securities pending an announcement related to a capital raise. This move indicates a potential strategic financial maneuver that could impact the company’s operations and market positioning, with implications for investors and stakeholders as they await further details.
OncoSil Medical Limited announced the results of a comparative analysis demonstrating the superiority of its OncoSil™ device over Stereotactic Body Radiation Therapy (SBRT) in treating locally advanced pancreatic cancer. The study showed that OncoSil™ significantly extends overall survival and progression-free survival compared to SBRT, with a higher rate of downstaging and surgical resection. These findings, presented at the Digestive Disease Week 2025, highlight the potential of OncoSil™ in treating earlier stages of pancreatic cancer and reinforce its efficacy and safety when added to standard chemotherapy. This development marks a significant milestone for OncoSil Medical, enhancing its positioning in the cancer treatment industry.
OncoSil Medical Ltd has announced the quotation of 2,076 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 5, 2025. This move is part of the company’s strategic efforts to enhance its market presence and potentially increase liquidity, reflecting its ongoing commitment to growth and value creation for its stakeholders.